Dr. Scott M. Rocklage as a medical specialists wakes up to either manage 5AM Venture’s portfolio, study and research life science innovations and areas of interest or attend Scientific board meetings. He is one man surrounded by a pool of professionals ranging from scientists, business experts and medical practitioners. In fact he once said during an interview that this crowd is what has helped him bring his ideas into reality.
Mr. Rocklage has been in the industry long enough to understand innovations and radicalism in disease management especially cancer. He has seen cancer treatment evolve over time and is particularly fascinated by invasive treatment methods targeting the genotypes, tumors and mutations. This has helped save lives among cancer patients. He has vast experience in laboratory research, clinical trial, healthcare management and leadership of healthcare facilities.
Apparently, he is the Managing Partner at 5AM Ventures where his medical career keeps blossoming. He says his time management and prioritization habits have had an upper arm in his success. Scott Rocklage advises entrepreneurs to evaluate the market well, measure risk involved in each entrepreneurial venture they intend to dive in and finally select and continuously empower their personnel or workforce. Learn more: https://www.crunchbase.com/person/scott-m-rocklage
About Dr. Scott M. Rocklage
He is a graduate of University of California, Berkeley where he obtained a Bachelor of Science degree in Chemistry. Scott Rocklage also has a PHD from Massachusetts Institute of Technology, his alma mater. He is currently is a significant figure of 5AM Venture Partners having joined in a capacity of a partner in 2003. The following year he was appointed as the Managing Partner a role he has held to date.
Prior to 5AM Ventures, the FDA approved healthcare management company, Dr. Scott M. Rocklage worked with several reputable institutions in the industry. He has worked for Nycomed Salutar and Cubist Pharmaceuticals as the President and CEO. Mr. Rocklage has also chaired executive board committees of NASDAQ:RLYP – Relypsa, Novira, Pulmatrix, Rennovia, Kinestral, and other affiliate companies of Amgen, Teleflex,and EntreMed. His major highlight of his career is when his research at MIT, Richard R. Schrock laboratory won his the Nobel Prize in Chemistry in 2005.